Financials TaiMed Biologics Inc.

Equities

4147

TW0004147004

Biotechnology & Medical Research

End-of-day quote Taipei Exchange 18:00:00 2024-06-13 EDT 5-day change 1st Jan Change
90.9 TWD -0.11% Intraday chart for TaiMed Biologics Inc. +0.89% +10.85%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 24,991 21,212 17,813 17,843 20,746 24,817 -
Enterprise Value (EV) 1 23,717 21,176 17,798 18,305 21,217 23,993 23,030
P/E ratio -43.1 x -115 x -37.8 x -66.1 x -106 x 95 x 23.9 x
Yield - - - - - - -
Capitalization / Revenue 35.5 x 29.4 x 43.1 x 31.7 x 42.2 x 17.4 x 12.7 x
EV / Revenue 33.7 x 29.3 x 43 x 32.5 x 43.1 x 16.8 x 11.8 x
EV / EBITDA -79.7 x 3,016 x -54 x -517 x -1,957 x 23.9 x 15.1 x
EV / FCF -30.5 x -83.3 x -81.1 x - -673 x -60.4 x 31.9 x
FCF Yield -3.28% -1.2% -1.23% - -0.15% -1.65% 3.14%
Price to Book 6.96 x 5.54 x 6.06 x 6.58 x 8.09 x 9.04 x 6.56 x
Nbr of stocks (in thousands) 252,183 252,220 252,311 252,374 252,999 273,010 -
Reference price 2 99.10 84.10 70.60 70.70 82.00 90.90 90.90
Announcement Date 3/26/20 3/26/21 3/31/22 3/10/23 3/20/24 - -
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net sales 1 704.5 722.5 413.4 563 491.8 1,424 1,949
EBITDA 1 -297.5 7.022 -329.7 -35.41 -10.84 1,003 1,527
EBIT 1 -390 -132.8 -486.4 -191.9 -166.2 295 1,180
Operating Margin -55.36% -18.38% -117.64% -34.08% -33.8% 20.71% 60.54%
Earnings before Tax (EBT) 1 -578.7 -183.3 -470.9 -269.3 -194.8 320.5 1,200
Net income 1 -578.7 -183.3 -470.9 -269.3 -194.8 241.7 960
Net margin -82.14% -25.37% -113.91% -47.83% -39.61% 16.97% 49.26%
EPS 2 -2.300 -0.7300 -1.870 -1.070 -0.7700 0.9570 3.800
Free Cash Flow 1 -776.9 -254.3 -219.4 - -31.54 -397 723
FCF margin -110.27% -35.2% -53.08% - -6.41% -27.88% 37.1%
FCF Conversion (EBITDA) - - - - - - 47.35%
FCF Conversion (Net income) - - - - - - 75.31%
Dividend per Share - - - - - - -
Announcement Date 3/26/20 3/26/21 3/31/22 3/10/23 3/20/24 - -
1TWD in Million2TWD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 75.86 40.67 99.28 96.58 326.5 71.77 104.2 157.6 158.2 178.9 132.5 187.5 196.5
EBITDA 1 -203.2 -63.11 -16.43 - - -32.02 -26.47 35.41 12.23 1.706 76 113 111
EBIT 1 -242.2 -102.2 -55.56 -59.41 25.33 -71.14 -65.3 -3.289 -26.5 -37.05 -38.5 -17 -13.5
Operating Margin -319.34% -251.31% -55.96% -61.52% 7.76% -99.13% -62.64% -2.09% -16.75% -20.7% -29.06% -9.07% -6.87%
Earnings before Tax (EBT) 1 -298.7 -119.8 -75.77 - - -80.8 -47.84 -5.878 -60.29 -16.04 -39 -17.5 -13
Net income 1 -298.7 -119.8 -75.77 -35.98 -37.78 -80.8 -47.84 -5.878 -60.29 -16.04 -37 -17.5 -15
Net margin -393.77% -294.47% -76.31% -37.25% -11.57% -112.59% -45.89% -3.73% -38.1% -8.96% -27.92% -9.33% -7.63%
EPS 2 -1.190 -0.4700 -0.3000 -0.1400 -0.1500 -0.3200 -0.1900 -0.0200 -0.2400 -0.0600 -0.1400 -0.0600 -0.0500
Dividend per Share - - - - - - - - - - - - -
Announcement Date 3/31/22 5/13/22 8/15/22 11/11/22 3/10/23 5/12/23 8/11/23 11/14/23 3/20/24 5/14/24 - - -
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 - - - 462 471 - -
Net Cash position 1 1,274 36.1 15.6 - - 824 1,787
Leverage (Debt/EBITDA) - - - -13.04 x -43.43 x - -
Free Cash Flow 1 -777 -254 -219 - -31.5 -397 723
ROE (net income / shareholders' equity) -15.1% -5.24% -14.8% -9.52% -7.38% 21.6% 31.8%
ROA (Net income/ Total Assets) -12.2% -3.69% -9.6% - -4.87% -0.5% 21.8%
Assets 1 4,761 4,964 4,904 - 3,997 -48,335 4,404
Book Value Per Share 2 14.20 15.20 11.70 10.70 10.10 10.10 13.90
Cash Flow per Share 2 -2.600 -0.8000 -0.8400 -2.400 -0.1000 -0.1400 4.210
Capex 1 122 53.6 8.17 - 5.94 100 100
Capex / Sales 17.25% 7.42% 1.98% - 1.21% 7.02% 5.13%
Announcement Date 3/26/20 3/26/21 3/31/22 3/10/23 3/20/24 - -
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
90.9 TWD
Average target price
137 TWD
Spread / Average Target
+50.74%
Consensus
  1. Stock Market
  2. Equities
  3. 4147 Stock
  4. Financials TaiMed Biologics Inc.